None
SEDAR Interim Financial Statements
DTC · Price
[
{
"companyName": "Defence Therapeutics Inc.",
"reportingPeriodEnd": "2025-12-31",
"reportStatus": "Unaudited",
"auditorName": null,
"auditorKeyMatters": [],
"balanceSheet": {
"cash": 947354,
"receivables": 222684,
"prepaids": 21769,
"totalCurrentAssets": 1191807,
"equipment": 177198,
"rightOfUseAsset": 0,
"totalNonCurrentAssets": 177198,
"totalAssets": 1369005,
"accountsPayableAndAccruedLiabilities": 1105403,
"convertibleDebenturesCurrent": 0,
"leaseObligationCurrent": 0,
"totalCurrentLiabilities": 1105403,
"convertibleDebenturesNonCurrent": 1487720,
"totalNonCurrentLiabilities": 1487720,
"totalLiabilities": 2593123,
"shareCapital": 25812447,
"shareBasedPaymentsReserve": 4029688,
"equityComponentOfConvertibleDebentures": 281558,
"accumulatedOtherComprehensiveIncome": -2768,
"deficit": -31345044,
"totalEquityDeficiency": -1224119,
"totalLiabilitiesAndEquity": 1369005,
"cashPerShare": 0.0171,
"workingCapitalPerShare": 0.0016
},
"incomeStatement": {
"shareBasedCompensation": 197436,
"researchAndLabFees": 432111,
"investorRelationsAndShareholderCommunication": 764174,
"managementFees": 140000,
"interestAccretion": 191575,
"consultingFees": 100913,
"accountingAndLegal": 176827,
"officeAndGeneral": 136261,
"transferAgentAndFilingFees": 43292,
"depreciationOfEquipmentAndRightOfUseAsset": 25515,
"foreignExchangeLossGain": 14258,
"totalExpenses": 2222362,
"interestIncome": 631,
"cumulativeTranslationAdjustment": -2768,
"netLossAndComprehensiveLoss": -2224499,
"basicAndDilutedLossPerShare": -0.04,
"weightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted": 55351943
},
"cashFlowStatement": {
"netLossForThePeriod": -2224499,
"depreciationOfEquipmentAndRightOfUseAsset": 6662,
"depreciationOfIntangibleAssets": 18853,
"interestAccretion": 191575,
"shareBasedCompensation": 197436,
"gainOnExtinguishmentOfDebentures": 0,
"changesInReceivables": -24632,
"changesInPrepaids": 11608,
"changesInAccountsPayableAndAccruedLiabilities": -297685,
"cashProvidedByUsedInOperatingActivities": -2120682,
"salePurchaseOfEquipmentNet": -15054,
"cashUsedInInvestingActivity": -15054,
"proceedsFromShareIssuance": 0,
"proceedsFromExerciseOfWarrants": 27750,
"shareIssueCosts": -615,
"proceedsFromLoanPayable": 0,
"proceedsFromIssuanceOfConvertibleDebentures": 2000000,
"repaymentsOfConvertibleDebentures": 0,
"transactionCosts": -160100,
"repaymentsOfLoanPayable": 0,
"repaymentOfLeaseObligation": -15069,
"cashUsedInFinancingActivities": 1851966,
"impactOfCurrencyTranslationOnCash": -1303,
"inflowOutflowOfCash": -285073,
"cashBeginningOfPeriod": 1232427,
"cashEndOfPeriod": 947354
},
"investmentsAndOtherAssets": [
{
"type": "Subsidiary",
"description": "Defence Therapeutics US LLC",
"ownershipPercentage": 100,
"value": null,
"notes": "Place of Incorporation: USA. Ownership % as at December 31, 2025: 100% (June 30, 2024: 0%)."
}
],
"shareStructure": {
"authorizedShares": "Unlimited Class A Common Shares",
"issuedShares": 57369970,
"classesOfShares": ["Class A Common Shares"],
"warrants": [
{
"number": 612360,
"exercisePrice": 2.00,
"expiryDate": "2026-01-30"
},
{
"number": 432000,
"exercisePrice": 2.00,
"expiryDate": "2026-03-22"
},
{
"number": 803000,
"exercisePrice": 1.00,
"expiryDate": "2026-10-30"
},
{
"number": 25000,
"exercisePrice": 1.00,
"expiryDate": "2026-11-29"
},
{
"number": 7400000,
"exercisePrice": 0.75,
"expiryDate": "2027-01-31"
},
{
"number": 3598667,
"exercisePrice": 0.75,
"expiryDate": "2027-09-15"
}
],
"options": [
{
"number": 25000,
"exercisePrice": 1.00,
"expiryDate": "2026-07-08"
},
{
"number": 200000,
"exercisePrice": 0.60,
"expiryDate": "2026-10-10"
},
{
"number": 200000,
"exercisePrice": 0.60,
"expiryDate": "2027-09-27"
},
{
"number": 100000,
"exercisePrice": 0.60,
"expiryDate": "2027-11-13"
},
{
"number": 100000,
"exercisePrice": 0.60,
"expiryDate": "2027-11-15"
},
{
"number": 100000,
"exercisePrice": 0.60,
"expiryDate": "2027-12-19"
},
{
"number": 100000,
"exercisePrice": 1.02,
"expiryDate": "2028-01-31"
},
{
"number": 100000,
"exercisePrice": 0.75,
"expiryDate": "2028-09-16"
},
{
"number": 100000,
"exercisePrice": 0.80,
"expiryDate": "2028-10-02"
},
{
"number": 1100000,
"exercisePrice": 2.50,
"expiryDate": "2033-10-06"
},
{
"number": 250000,
"exercisePrice": 1.02,
"expiryDate": "2035-01-31"
}
],
"rightsConvertibleInstruments": "Convertible Debentures: Principal $2,000,000, conversion price $0.60, maturity September 16, 2027."
},
"managementCompensation": {
"currency": "CAD",
"periods": {
"sixMonthsEndedDecember312025": {
"consultingFees": 76957,
"accountingAndLegal": 93500,
"managementFees": 140000,
"researchAndLabFees": 0,
"wagesAndSalaries": 115000,
"shareBasedCompensation": 197436,
"total": 622893
},
"sixMonthsEndedDecember312024": {
"consultingFees": 58400,
"accountingAndLegal": 0,
"managementFees": 226000,
"researchAndLabFees": 125000,
"wagesAndSalaries": 0,
"shareBasedCompensation": 159514,
"total": 569014
}
},
"namedIndividuals": [],
"otherRelatedPartyTransactions": [
{
"counterparty": "Companies controlled by current and former officers and directors",
"description": "Accounts payable",
"amount": 12886,
"period": "As at December 31, 2025"
},
{
"counterparty": "Companies in which management and directors are principals",
"description": "Research and lab fees paid",
"amount": 0,
"period": "Six months ended December 31, 2025"
}
]
},
"subsequentEvents": []
}
]
More from Defence Therapeutics Inc
May 19, 2026 · 03:16